glycerol/inflammation

FIELD OF THE INVENTION The invention relates generally to anti-inflammatory compositions and, more specifically, to anti-inflammatory compositions derived from marine algae having a high content of monogalactosyl dieicosapentaenoyl glycerol (MGDG-EPA.) BACKGROUND OF THE

FIELD OF THE INVENTION The invention relates generally to anti-inflammatory compositions and, more specifically, to anti-inflammatory compositions derived from marine algae having a high content of monogalactosyl dieicosapentaenoyl glycerol (MGDG-EPA). BACKGROUND OF THE

BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to anti-cancer drug and, more particularly, to synthetic dicinnamate compounds and their analogues that exhibit anti-tumor activity and/or an anti-inflammatory activity, that has beneficial activity principally in

FIELD OF THE INVENTION This inventions relates to pharmacologically-active, anti-inflammatory compounds, and more specifically to long aliphatic chain esters of selected zwitterionic organic compounds derived from naturally occurring taurine. This invention pertains to novel zwitterionic compounds

BACKGROUND TO THE INVENTION The present invention relates to a series of novel glycerol derivatives containing a heterocyclic system and provides processes for producing these compounds and compositions containing them for therapeutic use, especially for use as antagonists to platelet activating

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a national stage application (under 35 U.S.C. .sctn. 371) of PCT/SE2016/000066, filed Nov. 10, 2016, which claims benefit of European Application No. 1500460.9, filed Nov. 13, 2015, which are incorporated herein by reference in their

FIELD OF THE INVENTION This invention pertains to the synthesis and use as therapeutic agents of a group of substances with a glycerol backbone or aliphatic chain structure linked to phosphonocholine, phosphinocholine, phosphonoinositol, phosphinoinositol, or other phosphorus-containing head groups.

The present invention relates to 2,2-disubstituted glycerol and glycerol-like compounds, compositions containing such compounds, and methods of using such compounds. Various publications have disclosed related compounds. For example, the SCRIP PAF REPORT, PJB Publications, 1986 and Ann. Rep. Med.

The present invention relates to 2,2-disubstituted glycerol and glycerol-like compounds, compositions containing such compounds, and methods of using such compounds. Various publications have disclosed related compounds. For example, the SCRIP PAF REPORT, PJB Publications, 1986 and Ann. Rep. Med.

BACKGROUND OF THE INVENTION (1) Field of the Invention A subject matter of the present invention is a herbal preparation with anti-inflammatory and astringent effects used in a herbal medicine to treat conditions-related to interruption of anatomical continuity of outer layers of skin or deeper

Priority is claimed to provisional patent application Ser. No. 60/009,546, filed Jan. 2, 1996. TECHNICAL FIELD The present invention relates to certain alkyl and alkenyl glycerophosphoethanolamines substituted with a retinoid ester moiety on the glyceryl backbone, and to pharmaceutical compositions

TECHNICAL FIELD This invention relates to electrotransport agent delivery devices, compositions, and methods. More particularly, this invention relates to methods of reducing skin irritation during transdermal electrotransport agent delivery. BACKGROUND ART The term "electrotransport" as used herein

TECHNICAL FIELD This invention relates to electrotransport agent delivery devices, compositions, and methods. More particularly, this invention relates to methods of reducing skin irritation during transdermal electrotransport agent delivery. BACKGROUND ART The term "electrotransport" as used herein

FIELD OF THE INVENTION This invention relates to pharmaceutical preparations (which expression is herein intended to include veterinary preparations) for use in combating infective organisms afflicting the animal body (which expression is herein intended to include the human body). This invention

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation-in-part of PCT International Applications PCT/ZA01/00098, PCT/ZA01/00099, and PCT/ZA01/00100, all filed Jul. 19, 2001, and all designating the U.S. FIELD OF THE INVENTION This invention relates to pharmaceutical preparations